A new method for mapping DNA methylation in cells
Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping
This study is exploring a new technology to create detailed maps of how DNA changes in cells, which could help us understand diseases like cancer and brain disorders better, ultimately leading to better tests and treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Epicypher, INC. NIH-funded |
| Lab location | 1 site (Research Triangle Park, UNITED STATES) |
| Project ID | NIH-10815844 on NIH RePORTER |
What this research studies
This research focuses on developing an advanced technology called Targeted Enzymatic Methylation-sequencing (TEM-seqTM) to create detailed maps of DNA methylation patterns in cells. By utilizing innovative techniques that require fewer cells and less sequencing effort, the project aims to uncover how DNA methylation interacts with other chromatin features to regulate gene expression. This could lead to a better understanding of various diseases, including cancers and neurological disorders, by providing insights into the molecular mechanisms at play. Patients may benefit from improved diagnostic tools and targeted therapies based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancers or neurological disorders who are interested in novel diagnostic and therapeutic approaches.
Not a fit: Patients with conditions unrelated to DNA methylation or chromatin modifications may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostic tools and targeted treatments for various diseases, particularly cancers.
How similar studies have performed: Other research has shown promise in using advanced genomic mapping techniques, suggesting that this approach could yield significant insights.
Where this research is happening
Research Triangle Park, UNITED STATES
- Epicypher, INC. — Research Triangle Park, United States (Active)
Researchers
- Principal investigator: Keogh, Michael-Christopher — Epicypher, INC.
- Study coordinator: Keogh, Michael-Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.